ストックスクリーナーアプリを入手
3.60
1.98%
0.07
前日終値:
$3.53
開ける：
$3.6
24時間の取引高:
8,612
Relative Volume:
1.25
時価総額：
$77.90M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.53
$3.80
1週間の範囲:
$3.06
$3.9059
52週間の値動き範囲:
$3.06
$3.9059
Advanced Biomed Inc Stock (ADVB) Company Profile
ADVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADVB
Advanced Biomed Inc
|
3.60 | 77.90M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
516.99 | 195.34B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
208.57 | 149.60B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
119.29 | 33.84B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
412.67 | 33.52B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
183.82 | 32.24B | 15.41B | 1.37B | 2.11B | 7.50 |
Advanced Biomed Inc (ADVB) 最新ニュース
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies - Morningstar
Advanced Biomed Inc. Completes Successful IPO Launch - TipRanks
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket - Benzinga India
Red-hot market supports two med-tech IPOs in a day - BioWorld Online
A Dynamic Duo: Travis Stancil and Natella Devitskya Celebrate Five Years of Captivating Performances - The Manila Times
Advanced Biomed Inc. Announces Closing of Initial Public Offering Raising $6.56 Million - Nasdaq
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering - Benzinga
Advanced Biomed prices IPO at $4 per share - MSN
Advanced Biomed Prices 1.6 Million Shares to Raise $6.6 Million in IPO -March 06, 2025 at 09:29 am EST - Marketscreener.com
OverDrive Appoints Eric Miller to Lead the Company's Data and Information Science Services - The Manila Times
ADVB IPO NewsTaiwanese diagnostics developer Advanced Biomed prices downsized US IPO at the $4 low end - Renaissance Capital
Advanced Biomed Inc. Announces Pricing of Initial Public Offering - GlobeNewswire
This Cancer Detection Biotech Just Priced Its Nasdaq IPOKey Details Inside - StockTitan
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
IPO Roundup: Advanced Biomed, Brag House Holdings and more - MSN
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies - PR Newswire
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development - PR Newswire
Biomedical Engineering Courses: Admission 2025, Fees, Eligibility, Entrance Exams, Syllabus/Subjects, Top Colleges, Career Scope & Salary - Shiksha
Mainz Biomed Launches Major U.S. Study for AI-Powered Colorectal Cancer Detection Test - StockTitan
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab - Yahoo Finance
Orchestra BioMed shares get shot in the arm on solid clinical trial data - Mugglehead
Mainz Biomed Enters Agreement with Quest Diagnostics to Advance ColoAlert Colorectal Cancer Screening Test - Nasdaq
Fluid Biomed Inc. Raises $27 Million USD in Oversubscribed Series A Financing to Advance World’s First Bioabsorbable Polymer-Based Stent To Treat Brain Aneurysms - Business Wire
FBB Biomed partners with Verici Dx to advance research on neurologic diseases - Corridor Business
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - citybuzz -
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
L&K BIOMED Announces FDA Approval of the BluEX Lumbar Expandable Cage System, Featuring Advanced Surface Technology for Comprehensive Spine Interbody Fusion Options. - Becker's Orthopedic & Spine
Taiwanese diagnostics developer Advanced Biomed slashes deal size by 92% ahead of $9 million US IPO - Renaissance Capital
Thermoelectric Materials and Devices for Advanced Biomedical ApplicationsJia2024Small - Wiley Online Library
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors - PR Newswire
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies - Bayer
Polysaccharide-Based Hydrogels for Advanced Biomedical Engineering Applications - ACS Publications
Genexys BioMed Awarded $320K SBIR Grant to Advance Novel Cystic Fibrosis Gene Therapy - PR Newswire
Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test - News-Medical.Net
Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
Harnessing stimuli‐responsive biomaterials for advanced biomedical applicationsLiaoExploration - Wiley Online Library
Adroit Biomed Ltd. Announces Innovative, Technologically Advanced, High-Performance Collagen 'Fortisil C' - ETHealthWorld
Initial Public Offering (IPO) News Live Feed - StockTitan
4D Printing for Biomedical ApplicationsYarali2024Advanced Materials - Wiley Online Library
Crucial Breakthrough of BODIPY-Based NIR-II Fluorescent Emitters for Advanced Biomedical Theranostics - Wiley Online Library
Development and Application of an Advanced Biomedical Material‐Silk Sericin - Wiley Online Library
Research and development - Novartis
BrioHealth Solutions Launches New Corporate Identity and Prepares for Groundbreaking INNOVATE Trial for Advanced Heart Failure Treatment - PR Newswire
Leidos Biomedical Research - Leidos
AmplifyBio and Vector BioMed Partner to Manufacture Plasmids and Share Capabilities that Enhance the Safety and Scalability of Lentiviral-based Gene Therapeutics - Newswire
Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis - BioSpace
Offerings News Live Feed - StockTitan
Jacqueline Ciron Angeles, MD - The Manila Times
Taiwanese developer of microfluidic testing equipment for early cancer screening. - Renaissance Capital
Advanced Clinical Technology, Inc. (ACT) - MedTech Outlook
Advanced Biomed Inc (ADVB) 財務データ
Advanced Biomed Inc (ADVB) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.53%
0.15%
大文字化:
|
ボリューム (24 時間):